Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more

Midday movers were broadly positive, led by Vicor's 14% rally after it raised expected sequential Q3 revenue growth to more than 20% from nearly 10%, and On Holding's 10%+ gain on new 2029 targets of at least CHF5.6 billion in sales, a 65% gross margin and a $1 billion buyback authorization. Grab, Capri and Shopify each rose about 7% on CEO share purchases, potential-sale discussions and Meta AI-agent checkout integration, respectively, while Amgen gained more than 3% on positive Phase 3 Sjögren's trial results. The principal negative catalyst was CMS's plan to align Medicare lab reimbursement closer to private-payer rates after finding Medicare paid 16% more, sending Quest Diagnostics down 5.3% and Labcorp down 3.6%.

Analysis

The most durable repricing is negative for DGX and LH: a public-to-private reimbursement reset directly attacks a high-margin revenue pool and creates a template for further site-of-service and pricing scrutiny. The key unknown is each company’s Medicare exposure by test category and contractual pass-through ability; absent offsets, even a low-single-digit revenue reduction can translate into a materially larger EPS impact given laboratory fixed costs. Expect estimate-risk over the next 1-3 months as analysts quantify the rule, with 6-18 month downside if commercial payors use the federal benchmark in negotiations.

VICR’s revised trajectory matters because high-density power conversion is a bottleneck in AI compute racks, where power losses and thermal constraints have become more valuable than incremental semiconductor performance. The earnings setup can sustain a multiple expansion for 1-2 quarters if design-win conversion confirms that growth is AI-linked rather than a short-cycle industrial inventory rebound; the latter would make the sharp move vulnerable. SHOP’s agentic-commerce integration is strategically constructive but economically ambiguous: Meta may increase merchant conversion while retaining control over customer discovery, potentially limiting SHOP’s merchant-acquisition value capture.

LEN’s ownership signal is not itself an earnings catalyst; the more actionable implication is renewed investor focus on builders with land discipline if mortgage rates fall, though lower rates also revive resale inventory and pressure new-home pricing incentives. ONON’s long-duration margin ambition requires continued premium pricing while larger brands defend running and lifestyle share, so its move likely pulls forward execution that must be validated in quarterly gross-margin and inventory data. AMGN’s clinical result can create a differentiated immunology asset, but commercial value depends on durability, safety and positioning against established autoimmune biologics rather than the initial efficacy headline.

Key Decisions for Investors

• Initiate a 3-6 month short DGX / long UNH pair, sized modestly: DGX has direct reimbursement and operating-leverage risk, while UNH is a plausible beneficiary of lower lab unit costs. Reassess if DGX demonstrates that Medicare exposure is below expectations or guides to less than a 2% EPS impact.
• Maintain a 1-2 quarter tactical long VICR only on post-guidance consolidation; target further upside if upcoming results show >20% sequential growth and AI/data-center mix expansion. Stop on a revenue guide below the new trajectory, which would indicate the demand is cyclical rather than design-win driven.
• Do not chase LEN on the ownership disclosure. Prefer a basket long LEN and DHI only if mortgage rates decline materially without a comparable rise in existing-home listings; falsify the thesis if incentives increase or gross margins weaken despite lower rates.
• Avoid treating SHOP’s AI-commerce announcement as near-term monetization. Monitor disclosed conversion, payment-volume, or take-rate lift over the next two earnings reports; absent measurable economics, META captures more of the strategic optionality than SHOP.
• Treat CPRI as event-driven optionality rather than a standalone fundamental long: potential buyers face financing, brand-turnaround and antitrust constraints after the sector’s recent regulatory scrutiny. Use defined-risk call structures only after credible bid terms emerge, not on source-driven price strength.